Status:

ACTIVE_NOT_RECRUITING

SATURN Transcatheter Mitral Valve Replacement for Functional Mitral Regurgitation

Lead Sponsor:

InnovHeart

Conditions:

Mitral Regurgitation

Valve Heart Disease

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

This study is a prospective, single-arm, multi-center feasibility clinical study of the SATURN TA System for the treatment of NYHA Class ≥ II patients with severe functional mitral regurgitation who a...

Eligibility Criteria

Inclusion

  • Age 18 years or older.
  • Severe functional mitral regurgitation (≥ Grade 3+).
  • NYHA functional Class ≥ II. If Class IV, patient must be ambulatory.
  • Treatment and compliance with optimal guideline-directed medical therapy (GDMT) for heart failure for at least 30 days.
  • Not a suitable candidate for open mitral valve surgery due to high operative risk, as determined by the Heart Team.
  • Able to complete quality-of-life assessment (KCCQ).
  • General

Exclusion

  • Excessive frailty or comorbid conditions that preclude the anticipated benefit of the valve replacement.
  • Life expectancy \<1 yr due to noncardiac conditions.
  • Active endocarditis.
  • Active systemic infection.
  • Modified Rankin Scale ≥4 disability.
  • Hemodialysis/ chronic renal failure (eGFR \< 35 mL/min/m2).
  • Pulmonary arterial hypertension (fixed PAS \< 60mmHg). 8) COPD on home oxygen.
  • 9\) Refuses blood transfusions. 10) Documented bleeding or coagulation conditions (hypo- or hyper-coagulable states).
  • 11\) Severe connective tissue disease under chronic immunosuppressive or cortisone therapy.
  • 12\) Pregnant/ lactating. Females of childbearing age must be willing to take contraceptives.
  • 13\) Participating in other investigational studies likely to confound the results or affect the study.
  • 14\) Unable to consent. 15) Unable or unwilling to comply with study Follow-up. 16) Patients classified as "vulnerable patients".
  • Cardiovascular

Key Trial Info

Start Date :

August 19 2020

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2024

Estimated Enrollment :

20 Patients enrolled

Trial Details

Trial ID

NCT04464876

Start Date

August 19 2020

End Date

December 1 2024

Last Update

May 22 2024

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Rigshospitalet University Hospital of Copenhagen

Copenhagen, Denmark

2

Heart And Vascular Center, Semmelweis University

Budapest, Hungary

3

Vilnius University Hospital Santaros klinikos

Vilnius, Lithuania